Why FDA’s capitulation of genetic therapy is such a big deal

October 12, 2017, 7:32 PM|
On Thursday, an FDA advisory row gave the immature light for a therapy that could urge the prophesy of people who have a singular genetic commotion called Leber’s inborn amaurosis (LCA). CBS News medical writer Dr. Tara Narula weighs in.

Check Also

NHS cancer specialists ‘too bustling manning the phones’

‘Highly qualified’ radiographers found ‘being put in charge of usurpation desks’ Cancer Research UK likely NHS’s …